PersonFounderExecutive
Mathai Mammen
Mathai Mammen is the Chairman, CEO and President of Parabilis Medicines (formerly FogPharma), a Cambridge biotech going after cancer targets long written off as undruggable. A trained physician-chemist who co-founded Theravance out of grad school and later ran R&D at Merck and Johnson & Johnson, he has had a hand in the discovery or development of roughly 19 approved medicines. At Parabilis he is betting on Helicon peptides - engineered molecules that slip inside cells to hit protein-protein interfaces small molecules and antibodies cannot reach.
drug discoverybiotechoncologyparabilis medicinesfogpharmahelicon peptides
